B
Bull
Bull · 25%RGC
$19.32
情境價格
$5.500
-0.010 (-0.18%)收盤時
Loading chart…
- High
- 5.500
- Open
- 5.420
- VWAP
- 5.41
- Vol
- 102.05K
- Mkt Cap
- 45.81M
- Low
- 5.220
- Amount
- 551.76K
- EV/EBITDA, TTM
- 0.00
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
AI analysis of Regencell Bioscience Holdings Ltd (RGC)
holdRegencell Bioscience Holdings Ltd is not a strong buy at the moment due to its significant year-to-date decline of 73.22% and a negative P/E ratio of -492.40, indicating ongoing financial struggles. The current price of 5.5 is close to its Fibonacci support level of 5.173, suggesting potential downside risk. However, the recent surge of 35% amid a short squeeze indicates volatility and potential for short-term gains, but long-term prospects remain uncertain.
Analyst Ratings (15)
Buy
9 Buy
5 Hold
1 Sell
Current: 5.50
最低
—
平均
—
最高
—
估值指標
The current forward P/E ratio for Regencell Bioscience Holdings Ltd (RGC) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for RGC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
2.007-01seekingalphaRegencell Bioscience Shares Surge 35% Amid Short Squeeze
7.006-23PRnewswireRegencell Bioscience Faces Class Action Lawsuit
7.006-23GlobenewswireRegencell Bioscience Class Action Alert for Investors
- 7.006-23PRnewswire
Regencell Securities Class Action Reminder
- 7.006-22Globenewswire
Regencell Faces Class Action Lawsuit for Investor Rights
RGC FAQ — answered by Alphio AI
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).
Regencell Bioscience Holdings Ltd is not a strong buy at the moment due to its significant year-to-date decline of 73.22% and a negative P/E ratio of -492.40, indicating ongoing financial struggles. The current price of 5.5 is close to its Fibonacci support level of 5.173, suggesting potential downside risk. However, the recent surge of 35% amid a short squeeze indicates volatility and potential for short-term gains, but long-term prospects remain uncertain.
15 analysts cover RGC: 9 rate it Buy, 5 Hold and 1 Sell.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。